Company intelligence / Profile preview
Shenyang Sunshine Pharmaceutical Co., LTD.
Shenyang, Liaoning, China3sbio.com ↗
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
01
Overview
Phase 3 trial of nofazinlimab (anti-PD-1) in first-line hepatocellular carcinoma completed enrollment, with topline results expected; DB-1303 (HER2 ADC) in pivotal Phase 3 for breast cancer in China. Several recombinant biologics and biosimilars are marketed for hematology and infectious diseases.
- Therapeutic areas
- OncologyInfectious DiseasesHematologyOphthalmology
- Modalities
- Monoclonal antibodyBispecific antibodyBiosimilarSmall moleculeProtein therapeuticsSynthetic proteinColony-stimulating factorBiological productAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Shenyang Sunshine Pharmaceutical Co., LTD..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyang Sunshine Pharmaceutical Co., LTD..